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1. INTRODUCTION {#cam43264-sec-0005}
===============

Renal cell carcinoma (RCC) is a common malignant tumor in the urinary system.[^1^](#cam43264-bib-0001){ref-type="ref"} 4%‐10% of cases of local advanced RCC are concomitant with inferior vena cava (IVC) tumor thrombus (TT).[^2^](#cam43264-bib-0002){ref-type="ref"}, [^3^](#cam43264-bib-0003){ref-type="ref"}, [^4^](#cam43264-bib-0004){ref-type="ref"} For some cases of RCC with concomitant venous tumor thrombus (VTT), bland thrombus (BT) may be present at the same time. BT is a nontumor thrombus, mainly composed of activated platelets, macrophages, and fibrin.[^5^](#cam43264-bib-0005){ref-type="ref"} Its formation mechanism is unclear and may be related to stasis or hypercoagulability of venous blood.[^6^](#cam43264-bib-0006){ref-type="ref"} After the tumor cells enter the blood, they may activate the platelets. The activated platelets combine with the tumor cells forming TTs, which can enhance the ability of tumor cells to adhere to the vascular endothelial cells and protect the tumor cells from blood flow.[^7^](#cam43264-bib-0007){ref-type="ref"}, [^8^](#cam43264-bib-0008){ref-type="ref"}, [^9^](#cam43264-bib-0009){ref-type="ref"} The presence of BT increases the difficulty of diagnosis and surgical treatment for patients with RCC and VTT.[^10^](#cam43264-bib-0010){ref-type="ref"}, [^11^](#cam43264-bib-0011){ref-type="ref"} It is reported that BT is associated with adverse survival outcomes in patients with RCC and VTT. In multiple‐matching, propensity‐score‐matched cohorts, the presence of BT was associated with lower median cancer‐specific survival (CSS) (28.1 vs 76.7 months, *P* \< .001).[^2^](#cam43264-bib-0002){ref-type="ref"}

In this study, we present the clinical characteristics of RCC with VTT and BT, and the influence of BT on the surgery and CSS for RCC with VTT.

2. PATIENTS AND METHODS {#cam43264-sec-0006}
=======================

2.1. Patients {#cam43264-sec-0007}
-------------

We retrospectively reviewed the clinical data of 153 patients with RCC and VTT between February 2015 and May 2018. One hundred and twenty‐three patients, who underwent surgical treatment and were diagnosed pathologically with RCC, were included in this study. The inclusion criteria were as follows: (a) imaging examination showed that renal tumor was accompanied by VTT; (b) patients underwent radical nephrectomy and IVC thrombectomy; and (c) postoperative pathological type was RCC. The exclusion criteria were as follows: (a) patients with recurrent TT after radical nephrectomy who only underwent IVC thrombectomy; and (b) patients who were lost to follow‐up. The procedure for patient selection is shown in the Figure [S1](#cam43264-sup-0001){ref-type="supplementary-material"}. None of the enrolled patients were treated with targeted drugs before surgery. Among 123 patients enrolled, 21 patients had concomitant BT and 102 had no BT. In the 21 patients with BT, there were 16 men and five women. Thirteen renal tumors were located on the right side and eight on the left. According to Mayo classification,[^2^](#cam43264-bib-0002){ref-type="ref"} one patient had level I VTT, 10 had level II VTT, five had level III VTT, and five had level IV VTT. The present study was approved by the Institutional Ethics Committee of our hospital.

The clinical manifestations of the patients were recorded, including local and systemic symptoms. Before surgery, B‐ultrasound was performed to evaluate the tumor\'s side, location, diameter, and relationship with renal vessels and collecting system. Enhanced magnetic resonance imaging (MRI) was performed to evaluate the length and invasion of VTT and the presence of BT. Thoracic and abdominal computed tomography (CT) was performed. Hemoglobin, leukocyte count, neutrophil count, lymphocyte count, platelet count, total protein, albumin, serum calcium, blood urea nitrogen, serum creatinine, and alkaline phosphatase were measured before surgery. Blood creatinine was re‐evaluated 1 week after surgery. For patients with clinical symptoms, MRI or bone scan was performed to exclude central nervous system or bone metastasis.

In this study, BT was initially diagnosed by preoperative enhanced CT and/ or enhanced MRI, and then confirmed by postoperative pathological examination. The imaging diagnostic criteria of VTT with BT are shown in Table [1](#cam43264-tbl-0001){ref-type="table"}. In the delayed phase of enhanced MRI, BT showed no obvious enhancement, while VTT usually showed enhancement. This was the most important difference between BT and VTT.

###### 

The imaging diagnostic criteria of venous tumor thrombus combined with bland thrombus

  Item                        Content                                                                    TT                                     BT
  --------------------------- -------------------------------------------------------------------------- -------------------------------------- -------------------
  Enhanced CT                 Width of the involved vein                                                 Widened                                Widened or normal
  Shape of thrombus           Irregular                                                                  Regular                                
  The edge of thrombus        Rough                                                                      Smooth                                 
  Enhanced scanning           Enhanced                                                                   Not enhanced; relatively low density   
  Enhanced MRI                T1WI sequence                                                              Low signal                             High signal
  T2WI sequence               Uneven signal                                                              Uniform signal                         
  DWI sequence                Local or total high signal                                                 Low signal                             
  Contrast‐enhanced imaging   Uneven enhancement; enhanced degree similar to tumor; neovascularization   No enhancement; low signal             

Abbreviations: BT, bland thrombus; CT, computed tomography; MRI, magnetic resonance imaging; TT, tumor thrombus.
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2.2. Surgical method {#cam43264-sec-0008}
--------------------

For patients with RCC and VTT concomitant with BT, the surgical procedure was determined according to the location and extent of BT (Table [2](#cam43264-tbl-0002){ref-type="table"}).

###### 

Bland thrombus classification according to the relative position of bland thrombus

+-------------------+------------------------------------+---------------+-----------------------------------+-----------------------------------+
| BT classification | Definition                         | Number, n (%) | Preoperative diagram              | Postoperative diagram             |
+===================+====================================+===============+===================================+===================================+
| Group A           | Proximal end BT                    | 1 (4.8%)      | ![](CAM4-9-5860-g003.jpg "image") | ![](CAM4-9-5860-g004.jpg "image") |
+-------------------+------------------------------------+---------------+-----------------------------------+-----------------------------------+
| Group B           | BT in the contralateral renal vein | 2 (9.5%)      | ![](CAM4-9-5860-g005.jpg "image") | ![](CAM4-9-5860-g006.jpg "image") |
+-------------------+------------------------------------+---------------+-----------------------------------+-----------------------------------+
| Group C           | Distal end BT                      | 12 (57.1%)    | ![](CAM4-9-5860-g007.jpg "image") | ![](CAM4-9-5860-g008.jpg "image") |
+-------------------+------------------------------------+---------------+-----------------------------------+-----------------------------------+
| Group D           | Multiple BT                        | 6 (28.6%）    | ![](CAM4-9-5860-g009.jpg "image") | ![](CAM4-9-5860-g012.jpg "image") |
|                   |                                    |               |                                   |                                   |
|                   |                                    |               | ![](CAM4-9-5860-g010.jpg "image") |                                   |
|                   |                                    |               |                                   |                                   |
|                   |                                    |               | ![](CAM4-9-5860-g011.jpg "image") |                                   |
+-------------------+------------------------------------+---------------+-----------------------------------+-----------------------------------+

Abbreviation: BT, bland thrombus.

John Wiley & Sons, Ltd

For distal end BT of IVC, if the BT was short, it could be removed with the VTT. If the BT was long, transverse resection of the IVC was required (Figure [1](#cam43264-fig-0001){ref-type="fig"}). For patients with IVC wall invasion, we excised the wall of the IVC and the VTT, and sutured the wall of the IVC. The outflow tract of the contralateral renal vein to the IVC was preserved. The distal end of the IVC was incised with scissors and sutured with a 3‐0 vascular suture. BT in the distal end of the transverse incision remained in the IVC.

![A 58‐year‐old man with right renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus (TT). (A) Abdominal enhanced magnetic resonance imaging (coronal position) showed the widening of the IVC and TT in the lumen (red arrow). The extent of IVC involvement was about 11.6 cm. Filling defect was seen at the entrance of renal vein into IVC and distal end of the IVC, suggesting the presence of bland thrombosis (BT) (black arrow). (B) Exposure of IVC and related vessels: distal end of IVC, contralateral renal artery or vein, proximal end of IVC. BT in the right renal vein and IVC. The distal end of the IVC and bilateral common iliac and external iliac veins had BTs. (C) We exposed the IVC by dissociating the duodenum to the inside of the abdomen. We transected the distal end of the IVC, contralateral renal vein, and proximal end of the IVC. The right kidney and the TT were removed completely. (D) Postoperative gross specimen showed right renal tumor and IVC TT combined with distal BT](CAM4-9-5860-g001){#cam43264-fig-0001}

For proximal end BT of IVC, the top of the BT was accurately determined during the operation, and intraoperative ultrasound was used to assist the diagnosis if necessary. The IVC needed a careful operation to reduce compression as much as possible, so as to avoid displacement of the BT, which may cause pulmonary embolism. The distal end of the IVC, the contralateral renal vein and the proximal end of the IVC were blocked with a vascular blocking band. After the IVC was cut, the VTT and BT were carefully removed to ensure the integrity of the BT.

For BT in the contralateral renal vein, or short BT in the distal end of the IVC, the distal end of the IVC, contralateral renal vein and proximal end of the IVC were blocked with a vascular blocking band during the operation. After the IVC was cut, the VTT and BT were completely removed.

2.3. Postoperative complications and follow‐up {#cam43264-sec-0009}
----------------------------------------------

Postoperative complications were recorded. The patients were followed up once every 6 months until year 5, and once every year thereafter. The follow‐up included biochemical analysis (renal function), urinary enhanced CT, and chest X‐ray.

2.4. Statistical analysis {#cam43264-sec-0010}
-------------------------

For comparison of categorical variables, Chi‐square tests were used. For comparison of continuous variables, the Mann‐Whitney *U* test was used. Univariable log‐rank tests and multivariable Cox regressions were conducted to evaluate the prognostic significance of each variable with respect to CSS. Kaplan‐Meier plots were performed to evaluate the influence of BT on CSS. All the statistical analyses were performed using SPSS version 22.0. A *P* value \<.05 was considered statistically significant.

3. RESULTS {#cam43264-sec-0011}
==========

The clinical and pathological data of patients are shown in Table [3](#cam43264-tbl-0003){ref-type="table"}. Compared with non‐BT patients, 21 patients (17.1%) with BT had longer operative time (416.76 ± 103.61 vs 314.86 ± 123.00 min, *P* = .001), more surgical blood loss (2738.10 ± 2238.41 vs 1090.98 ± 1395.21 mL, *P* = .004), more red blood cell transfusion (1933.33 ± 2036.99 vs 624.51 ± 926.87 mL, *P* = .009), more plasma transfusion (619.05 ± 831.64 vs 171.57 ± 390.07 mL, *P* = .025), larger maximum width of VTT (32.29 ± 7.01 vs 20.28 ± 8.94 mm, *P* \< .001), larger width of VTT at the entrance of the renal vein (26.99 ± 4.47 vs 17.86 ± 6.74 mm, *P* \< .001), higher proportion of open surgery (81.0% vs 47.1%, *P* = .006), higher rate of IVC transverse resection (57.1% vs 9.8%, *P* = .001), and higher incidence of postoperative complications (71.4% vs 27.5%, *P* = .011). RCC with VTT and BT increased the difficulty of surgery.

###### 

Comparison of clinical and pathologic characters between bland thrombus (BT) patients and non‐BT patients

                                                                      Non‐BT (n = 102)    BT patients (n = 21)   *P* value
  ------------------------------------------------------------------- ------------------- ---------------------- -----------
  Gender, n (%)                                                                                                  1.000
  Male                                                                76 (74.5%)          16 (76.2%)             
  Female                                                              26 (25.5%)          5 (23.8%)              
  Age, y, mean ± SD                                                   58.56 ± 10.56       59.00 ± 13.89          .870
  BMI, kg/m^2^, mean ± SD                                             23.56 ± 4.00        23.93 ± 3.68           .696
  Side, n (%)                                                                                                    .340
  Left                                                                41 (40.2%)          8 (38.1%)              
  Right                                                               61 (59.8%)          13 (61.9%)             
  ASA grade, n (%)                                                                                               .335
  1                                                                   8 (7.8%)            0 (0%)                 
  2                                                                   81 (79.4%)          12 (57.1%)             
  3                                                                   13 (12.7%)          9 (42.9%)              
  Clinical symptoms, n (%)                                                                                       .126
  No clinical symptoms                                                29 (28.4%)          3 (14.3%)              
  Local symptoms                                                      42 (41.2%)          10 (47.7%)             
  Systemic symptoms                                                   15 (14.7%)          2 (9.5%)               
  Both                                                                16 (15.7%)          6 (28.5%)              
  Clinical N stage, n (%)                                                                                        .336
  cN0                                                                 48 (47.1%)          7 (33.3%)              
  cN1                                                                 54 (52.9%)          14 (66.7%)             
  Clinical M stage, n (%)                                                                                        
  cM0                                                                 70 (68.6%)          14 (66.7%)             .304
  cM1                                                                 32 (31.4%)          7 (33.3%)              
  Mayo classification, n (%)                                                                                     \<.001
  0                                                                   28 (27.5%)          0 (0%)                 
  I                                                                   34 (33.3%)          1 (4.8%)               
  II                                                                  24 (23.5%)          10 (47.6%)             
  III                                                                 9 (8.8%)            5 (23.8%)              
  IV                                                                  7 (6.9%)            5 (23.8%)              
  Hemoglobin, g/L, mean ± SD                                          122.89 ± 23.76      112.38 ± 19.44         .060
  Platelet count, ×10^9^/L, mean ± SD                                 245.34 ± 100.82     230.00 ± 73.81         .510
  Serum calcium, mg/dL, mean ± SD                                     8.71 ± 0.81         8.55 ± 0.47            .405
  Albumin, g/L, mean ± SD                                             38.29 ± 5.88        38.32 ± 5.67           .982
  Alkaline phosphatase, U/L, mean ± SD                                93.46 ± 47.35       103.43 ± 60.28         .404
  Preoperative serum creatinine, µmol/L, mean ± SD                    97.88 ± 56.98       103.71 ± 27.14         .648
  Tumor diameter, cm, mean ± SD                                       8.94 ± 3.50         7.64 ± 2.84            .113
  Maximum width of VTT, mm, mean ± SD                                 20.28 ± 8.94        32.29 ± 7.01           \<.001
  The width of VTT at the entrance of the renal vein, mm, mean ± SD   17.86 ± 6.74        26.99 ± 4.47           \<.001
  Surgical approach, n (%)                                                                                       .006
  Laparoscope                                                         54 (52.9%)          4 (19.0%)              
  Open                                                                48 (47.1%)          17 (81.0%)             
  IVC transverse resection, n (%)                                                                                .001
  No                                                                  92 (90.2%)          9 (42.9%)              
  Yes                                                                 10 (9.8%)           12 (57.1%)             
  Operative time, min, mean ± SD                                      314.86 ± 123.00     416.76 ± 103.61        .001
  Surgical blood loss, mL, mean ± SD                                  1090.98 ± 1395.21   2738.10 ± 2238.41      .004
  Red blood cell transfusion, mL, mean ± SD                           624.51 ± 926.87     1933.33 ± 2036.99      .009
  Plasma transfusion, mL, mean ± SD                                   171.57 ± 390.07     619.05 ± 831.64        .025
  Pathology type, n (%)                                                                                          .747
  Clear cell RCC                                                      86 (84.3%)          17 (81.0%)             
  Non‐clear cell RCC                                                  16 (15.7%)          4 (19.0%)              
  Sarcomatoid differentiation, n (%)                                  18 (17.6%)          4 (19.0%)              1.000
  Serum creatinine one week after operation, µmol/L, mean ± SD        113.13 ± 102.98     167.62 ± 203.73        .245
  Postoperative complication, n (%)                                   28 (27.5%)          15 (71.4%)             .011
  Postoperative adjuvant targeted therapy, n (%)                      60 (58.8%)          11 (52.4%)             .814

John Wiley & Sons, Ltd

There was no significant difference between BT and non‐BT patients in gender, tumor side, age, clinical symptoms, American Society of Anesthesiologists (ASA) grade,[^12^](#cam43264-bib-0012){ref-type="ref"} body mass index (BMI), or tumor diameter. The proportion of high‐level VTT (Mayo level II‐IV) in the BT group was 95.2%, compared with 39.2% in the non‐BT group. There was no significant difference in clinical N or M stage, pathological type, pathological grade, or sarcomatoid differentiation.

Twenty‐one patients were classified according to the relative position of BT (Table [2](#cam43264-tbl-0002){ref-type="table"}). Group A (proximal end BT of the IVC) had one patient (4.8%), Group B (BT in the contralateral renal vein) had two patients (9.5%), and Group C (distal end BT of the IVC) had 12 patients (57.1%). The average length of BT was 10.39 ± 5.92 cm (range: 1.5‐20 cm). Group D had six patients (28.6%). Four patients had BT in the contralateral renal vein and distal end of the IVC. One patient had BT in the distal and proximal ends of IVC. One patient had BT in the distal and proximal ends of the IVC and contralateral renal vein.

Distant metastasis (hazard ratio \[HR\] = 3.356, *P* = .004), sarcomatoid differentiation (HR = 6.875, *P* \< .001), clear cell RCC (HR = 3.171, *P* = .015), elevated alkaline phosphatase (HR = 2.543, *P* = .029), and BT (HR = 3.323, *P* = .007) were independent risk factors for prognosis (Table [4](#cam43264-tbl-0004){ref-type="table"}). The mean CSS of non‐BT patients was 31.7 ± 1.9 months, while that of BT patients was 18.8 ± 1.8 months (*P* = .041) (Figure [2](#cam43264-fig-0002){ref-type="fig"}).

###### 

Prognosis factors for renal cell carcinoma patients with venous tumor thrombus

  Items                                                           Univariable analysis   Multivariable analysis                                   
  --------------------------------------------------------------- ---------------------- ------------------------ -------- ------- -------------- --------
  M1 stage                                                        3.499                  1.726‐7.091              \<.001   3.356   1.488‐7.568    .004
  Mayo classification                                             2.207                  1.439‐3.385              \<.001   ---     ---            .830
  Maximum width of tumor thrombus                                 1.158                  1.085‐1.236              \<.001   ---     ---            .986
  Operative approach                                              2.157                  1.023‐4.547              .043     ---     ---            .884
  IVC resection                                                   6.900                  2.336‐20.379             \<.001   ---     ---            .361
  Operative time                                                  1.007                  1.003‐1.011              .001     ---     ---            .761
  Surgical bleeding volume                                        1.000                  1.000‐1.001              .001     1.000   1.000‐1.001    .043
  Surgical blood transfusion volume                               1.001                  1.000‐1.001              .001     ---     ---            .654
  Plasma transfusion volume                                       1.001                  1.000‐1.002              .002     ---     ---            .915
  The width of tumor thrombus at the entrance of the renal vein   1.236                  1.109‐1.379              \<.001   1.220   1.089‐1.366    .001
  Sarcomatoid differentiation                                     4.039                  1.962‐8.314              \<.001   6.875   2.907‐16.260   \<.001
  Clear cell RCC                                                  2.850                  1.337‐6.075              .007     3.171   1.257‐7.999    .015
  Elevated alkaline phosphatase                                   3.120                  1.474‐6.604              .003     2.543   1.102‐5.869    .029
  BT                                                              2.271                  1.008‐5.121              .048     3.323   1.378‐8.012    .007

Abbreviations: BT, bland thrombus; CI, confidence interval; HR, hazard ratio; RC, renal cell carcinoma.

John Wiley & Sons, Ltd

![Cancer‐specific survival of bland thrombus (BT) and non‐BT patients](CAM4-9-5860-g002){#cam43264-fig-0002}

4. DISCUSSION {#cam43264-sec-0012}
=============

Preoperative imaging is important for diagnosis and determination of the extent of BT in patients with RCC with VTT. However, it is easy to misdiagnose or miss BT by imaging. There are similarities between the morphological characteristics of BT and VTT. The main ways to distinguish BT from VTT preoperatively are as follows: (a) Contrast‐enhanced CT: the venous lumen containing VTT becomes wider; the shape of the VTT is irregular, and its edge is mostly rough. After contrast‐enhanced scanning, the lesions in the lumen can be seen to enhancement. BT can also be manifested as widening of the involved venous lumen, or as the normal lumen. Most BTs are regular in shape and smooth edged. After contrast‐enhanced scanning, the lesions in the lumen are generally not enhanced and show low density.[^13^](#cam43264-bib-0013){ref-type="ref"}, [^14^](#cam43264-bib-0014){ref-type="ref"} (b) Enhanced MRI of the IVC: in T1‐weighted imaging, VTT shows low signal intensity, while BT shows high signal intensity. In T2‐weighted imaging, VTT shows uneven signal intensity, while BT shows even signal intensity. In diffusion‐weighted imaging, VTT shows local or overall signal enhancement, while BT shows decreased signal intensity.[^11^](#cam43264-bib-0011){ref-type="ref"}, [^15^](#cam43264-bib-0015){ref-type="ref"} VTT shows uneven enhancement and its degree of enhancement is similar to that of the primary sites. Neovascularization shadows can be seen in the arterial phase, and BT usually shows no enhancement and low signal intensity. In the delayed phase of enhanced MRI, BT shows no obvious enhancement, while VTT usually shows enhancement, which is the most important basis for the identification of VTT and BT.

VTT combined with BT might increase the difficulty of surgical treatment.[^16^](#cam43264-bib-0016){ref-type="ref"}, [^17^](#cam43264-bib-0017){ref-type="ref"} The present study showed that RCC patients with VTT and BT had longer operating time, more surgical blood loss and more blood transfusion. The reasons might be as follows. (a) The proportion of high‐level VTTs in the BT group was higher, accounting for 95.2%, compared with 39.2% in the non‐BT group. The surgical complexity of high‐level VTT is greater than that of low‐level VTT. (b) In BT patients, the IVC usually had complete obstruction, and the rate of IVC transverse resection was higher. In these cases, balloon catheter or milking technique was not used to simplify the operation. (c) If BT was in the distal end of the IVC, it was easy to cause complete obstruction of the IVC. This led to formation of collateral venous circulation, with compensatory veins around the tumor, which caused more surgical blood loss. Therefore, our study suggests that VTT combined with BT might further increase the difficulty of surgery.

There are some specific surgical procedures for patients with BT. For BT in the proximal end of the IVC, renal vein TT in the contralateral side, or short segment TT in the distal end of the IVC, one should carefully remove the VTT and BT after IVC incision, and try to maintain the integrity of the thrombi. For BT in the distal end of the IVC, which has a long range of IVC involvement and cannot be removed during the operation, transverse resection of the IVC is usually required.[^18^](#cam43264-bib-0018){ref-type="ref"} The purpose of transverse resection is to prevent BT shedding and causing pulmonary embolism. Some studies have shown that the transverse resection of the IVC might lead to obstruction of IVC reflux, causing lower extremity edema, scrotal edema, and renal insufficiency.[^19^](#cam43264-bib-0019){ref-type="ref"} However, in this study, we thought that transverse resection of the IVC was safe and effective, and prevented BT from shedding and causing pulmonary embolism. BT in the distal end of the IVC can cause complete obstruction, and promote formation of collateral venous circulation. When the IVC is completely occluded, the branch veins undergo compensatory dilation, and collateral circulation is usually established. The gonadal vein, adrenal vein, and lumbar vein are the branches of left renal vein; therefore, segmental resection of the IVC has little effect on the left renal function. The right renal vein has fewer and thinner branches. When left renal TT invades the IVC wall, blood can flow from the right renal vein back into the distal end of the IVC after segmental or transverse resection of the IVC. In this circumstance, the collateral circulation channels, such as the lumbar veins, should be preserved as much as possible. If preoperative imaging does not show that the collateral circulation is established, the right renal vein can be reconstructed with an autogenous vein, bovine pericardial patch, or an artificial blood vessel.

The incidence of postoperative complications was 57.1% in patients with VTT and BT, compared with 27.5% in the non‐BT patients. Fifteen BT patients had postoperative complications: one, nine, three, and two patients had Clavien‐Dindo classification grade I, II, IV, and V complications, respectively.[^20^](#cam43264-bib-0020){ref-type="ref"} Five patients had serious complications (grade III‐V). Twenty‐eight non‐BT patients had postoperative complications: 4, 21, 1, and 2 patients had grade I, II, III, and IV complications respectively. The average CSS of patients with BT was significantly shorter than that of patients without BT, which suggests that BT is an independent risk factor for poor prognosis.[^21^](#cam43264-bib-0021){ref-type="ref"}, [^22^](#cam43264-bib-0022){ref-type="ref"}, [^23^](#cam43264-bib-0023){ref-type="ref"} Distant metastasis, sarcomatoid differentiation, clear cell RCC, elevated alkaline phosphatase, and BT were the independent risk factors for poor prognosis. Therefore, RCC patients with VTT and BT diagnosed by preoperative imaging need more close follow‐up.

The formation mechanism of BT is still unclear. Some urologists have speculated that RCC is an immunoreactive tumor and may develop an inflammatory, procoagulative surface that triggers formation of BT.[^24^](#cam43264-bib-0024){ref-type="ref"} The presence of BT may increase surgical difficulty or extend the operative time. During surgery, BT in the proximal IVC may drop off and cause pulmonary embolism.[^25^](#cam43264-bib-0025){ref-type="ref"} It was shown previously that almost half of BT patients required IVC ligation or segmental resection.[^5^](#cam43264-bib-0005){ref-type="ref"}, [^11^](#cam43264-bib-0011){ref-type="ref"} The presence of BT is related to more obvious clinical symptoms, more surgical blood loss, higher VTT Mayo level, more preoperative metastasis, poorer perioperative outcomes, worse pathological features, and poorer progression‐free survival and overall survival.[^5^](#cam43264-bib-0005){ref-type="ref"}, [^11^](#cam43264-bib-0011){ref-type="ref"}, [^24^](#cam43264-bib-0024){ref-type="ref"} However, no study has explained the mechanism, through which BT affects prognosis. Further studies are needed to explore this question.

There were some limitations to our study. First, it was retrospective and may have been subject to selection bias, and some factors may have affected the outcomes. Second, the surgical procedures were completed by different surgeons in our center, and this may have affected the outcomes of some surgical procedures. Third, the number of patients with BT was small, and classification of BT may not have been completely accurate. The numbers of patients with different classes of BT were small; thus we could not compare the effects of different BT classes on the surgical treatment and prognosis.

5. CONCLUSIONS {#cam43264-sec-0013}
==============

In the delayed phase of enhanced MRI, BT shows no obvious enhancement, while VTT usually does show enhancement. This is an important difference between BT and VTT on preoperative imaging. The presence of BT increases surgical difficulty, and is correlated with adverse survival outcomes in patients with RCC with VTT.
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